Health Policies

24 Items

All Items

  • Regional Formularies in Italy: current state and future perspectives

    Alberto Bortolami, Claudio Jommi, Filippo Bresciani, Luca Piccoli, Elisa Sangiorgi, Giovanna Scroccaro
    68-74
    DOI: https://doi.org/10.33393/grhta.2024.2677
  • HTA regulation: how is Italy moving?

    Francesca Patarnello
    51-54
    DOI: https://doi.org/10.33393/grhta.2024.3025
  • Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)

    Silvia Calabria, Manenti Lucio, Giulia Ronconi, Carlo Piccinni, Leonardo Dondi, Letizia Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, Nello Martini
    22-30
    DOI: https://doi.org/10.33393/grhta.2024.2696
  • The future of drugs distribution in the National Health System

    Massimo Medaglia, Giuliano Buzzetti, Marco Cossolo, Paola Deambrosis, Giovanna Scroccaro
    17-21
    DOI: https://doi.org/10.33393/grhta.2024.2619
  • A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

    Michele Basile, Ilaria Valentini, Roberto Attanasio, Renato Cozzi, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Renata Simona Auriemma, Ernesto De Menis, Felice Esposito, Emanuele Ferrante, Giuseppe Iatì, Diego Mazzatenta, Maurizio Poggi, Roberta Rudà, Fabio Tortora, Fabio Cruciani, Zuzana Mitrova, Rosella Saulle, Simona Vecchi, Paolo Cappabianca, Agostino Paoletta, Alessandro Bozzao, Marco Caputo, Francesco Doglietto, Francesco Ferraù, Andrea Gerardo Lania, Stefano Laureti, Stefano Lello, Davide Locatelli, Pietro Maffei, Giuseppe Minniti, Alessandro Peri, Chiara Ruini, Fabio Settanni, Antonio Silvani, Nadia Veronese, Franco Grimaldi, Enrico Papini, Americo Cicchetti
    1-16
    DOI: https://doi.org/10.33393/grhta.2024.2601
  • Orphan drugs in Italy: availability and time-to-access at regional level

    Maria Lucia Marino, Eva Alessi, Aurora Di Filippo, Barbara Polistena, Francesco Macchia, Federico Spandonaro, Francesco Trotta
    89-97
    DOI: https://doi.org/10.33393/grhta.2023.2641
  • Time to market access in Italy: duration of the P&R process for rare disease drugs

    Andrea Marcellusi, Paola Raimondo, Carlotta Galeone, Pier Luigi Canonico
    79-88
    DOI: https://doi.org/10.33393/grhta.2023.2610
  • Unmet need: definitions, literature evidence and implications for HTA

    Claudio Jommi, Michela Meregaglia, Carmine Pinto
    70-78
    DOI: https://doi.org/10.33393/grhta.2023.2624
  • Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members

    Eugenio Di Brino, Claudio Jommi
    40-45
    DOI: https://doi.org/10.33393/grhta.2023.2562
  • The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy

    Francesco Malandrini, Cesare Borroni, Michela Meregaglia, Massimiliano Sarra, Oriana Ciani
    12-17
    DOI: https://doi.org/10.33393/grhta.2023.2514
  • Drugs territorialization in the era of PNRR: perspectives, opportunities and considerations from a panel of experts

    Anna Maria Marata, Walter Marrocco, Emanuela Arcangeli, Mattia Battistini, Giuliano Buzzetti, Riccardo Candido, Gianluigi Casadei, Francesco Cattel, Arturo Cavaliere, Agostino Consoli, Giovanni Corrao, Guido Didoni, Mauro Di Gesù, Alberto Giovanzana, Matteo Lenzi, Massimo Medaglia, Marta Meloncelli, Stefano Palcic, Marcello Pani, Francesca Patarnello, Emanuele Pria, Dario Scaduto, Valeria Tozzi, Marco Zibellini, Elisa Crovato
    155-158
    DOI: https://doi.org/10.33393/grhta.2022.2495
  • Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness

    Francesca Patarnello, Emiliano Briante, Federico Villa
    117-122
    DOI: https://doi.org/10.33393/grhta.2022.2440
  • Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness

    Claudio Jommi, Giovanni Apolone, Giovanna Scroccaro, Valentina Acciai, Antonio Addis, Andrea Ardizzoni, Renato Bernardini, Alberto Bortolami, Alessia Brigido, Giuliano Buzzetti, Pier Luigi Canonico, Francesca Caprari, Stefano Centanni, Chiara Cernetti, Americo Cicchetti, Giorgio Corsico, Francesco Damele, Filippo De Braud, Sara Manurita, Francesco Saverio Mennini, Irene Olivi, Federica Parretta, Lara Pippo, Stefania Pulimeno, Massimo Riccaboni, Giuseppe Rossi, Cecilia Saleri, Alessandra Sinibaldi, Federico Spandonaro, Cristian Stefenoni, Elena Visentin, Pierluigi Viale, Giuseppina Zapparelli, Patrizia Popoli
    99-104
    DOI: https://doi.org/10.33393/grhta.2022.2475
  • The potential impact of PNNR on the management of patients with epilepsy

    Francesco Saverio Mennini
    1-3
    DOI: https://doi.org/10.33393/grhta.2022.2445
  • Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines

    José Manuel Martínez-Sesmero, Borja Smith, Julen Madurga
    68-72
    DOI: https://doi.org/10.33393/grhta.2022.2366
  • How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality

    Pierluigi Russo
    31-35
    DOI: https://doi.org/10.33393/grhta.2022.2350
  • Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

    Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi
    30
    DOI: https://doi.org/10.33393/grhta.2022.2383
  • Real-world data: how they can help to improve quality of care

    Giovanni Corrao, Giovanni Alquati, Giovanni Apolone, Andrea Ardizzoni, Giuliano Buzzetti, Giorgio W. Canonica, Pierfranco Conte, Elisa Crovato, Francesco Damele, Carlo La Vecchia, Aldo P. Maggioni, Alberto Mantovani, Michele Marangi, Walter Marrocco, Andrea Messori, Alessandro Padovani, Alessandro Rambaldi, Walter Ricciardi, Francesco Ripa di Meana, Federico Spandonaro, Valeria Tozzi, Giuseppe Mancia
    134-139
    DOI: https://doi.org/10.33393/grhta.2021.2286
  • New drug pricing criteria in Italy: considerations and proposals to support value and innovation

    Francesca Patarnello, Federico Villa
    131-133
    DOI: https://doi.org/10.33393/grhta.2021.2207
  • Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

    Claudio Jommi, Antonio Addis, Nello Martini, Elena Nicod, Marcello Pani, Annalisa Scopinaro, Sabine Vogler
    114-119
    DOI: https://doi.org/10.33393/grhta.2021.2278
  • The future of Funds for Innovative Medicines: results from a Delphi Study

    Claudio Jommi, Patrizio Armeni, Arianna Bertolani, Francesco Costa, Monica Otto
    22-28
    DOI: https://doi.org/10.33393/grhta.2021.2219
  • The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020

    Paola Raimondo, Giorgio Casilli, Martina Isernia, Dario Lidonnici, Roberto Ravasio, Virginia Ronco, Elena Lanati
    109-114
    DOI: https://doi.org/10.33393/grhta.2020.2173
  • Valorization of clinical trials from the Italian National Health Service perspective: definition and first application of a model to estimate avoided costs

    Americo Cicchetti, Domenico Addesso, Filippo Elvino Leone, Antonino Amato, Luca Angerame, Angelo D'Aversa, Mario Fraticelli, Carlo Nicora, Eleonora Sfreddo, Mariangela Fumarola, Roberta Porcino, Gabriella Cocciolo, Simona Re, Sergio Scaccabarozzi
    26-32
    DOI: https://doi.org/10.33393/grhta.2020.709
  • Value-based healthcare: Il nuovo approccio di AIFA alla determinazione multidimensionale del valore AIFA’s new approach to multidimensional value determination

    Oriana Ciani, Carlo Federici, Giulia Fornaro, Carla Rognoni
    9-13
    DOI: https://doi.org/10.33393/grhta.2020.2102